SFB 1243 Cancer Evolution
print


Breadcrumb Navigation


Content
Greif, Philipp A.

Dr. Philipp A. Greif

Medizinische Klinik und Poliklinik III, Ludwig-Maximilians-Universität München

Contact

Klinikum der Universität München
Medizinische Klinik und Poliklinik III
Experimentelle Leukämie- und Lymphomforschung (ELLF)
Max-Lebsche-Platz 30
81377 München

Phone: +49 (0)89 4400-43982
Fax: +49 (0)89 4400 4 3970

Website: Medizinische Klinik III: Pathogenese der Akuten Leukämie

Work group

A08 Evolution of transcription factor mutations in myeloid leukemias

10 Major publications related to project

(See publications for recent papers published in the SFB context since 2016)

Neumann M, Vosberg S, Schlee C, Heesch S, Schwartz S, Gökbuget N, Hoelzer D, Graf A, Krebs S, Bartram I, Blum H, Brüggemann M, Hecht J, Bohlander SK, Greif PA∗ and Baldus CD∗ (2015). Mutational spectrum of adult T-ALL. Oncotarget, 6, 2754-66. *joint senior authors

Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, Schneider S, Hubmann M, Zellmeier E, Ksienzyk B, Jurinovic V, Pasalic Z, Kakadia PM, Dufour A, Graf A, Krebs S, Blum H, Sauerland MC, Büchner T, Berdel WE, Woermann BJ, Bornhäuser M, Ehninger G, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, and Greif PA (2014). Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood, 124, 1304-11.

Neumann M, Heesch S, Schlee C, Schwartz S, Gökbuget N, Hoelzer D, Konstandin NP, Ksienzyk B, Vos-berg S, Graf A, Krebs S, Blum H, Raff T, Brüggemann M, Hofmann WK, Hecht J, Bohlander SK, Greif PA* and Baldus CD* (2013). Whole exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood, 121, 4749-52. *joint senior authors

Opatz S, Polzer H, Herold T, Konstandin NP, Ksienzyk B, Zellmeier E, Vosberg S, Graf A, Krebs S, Blum H, Hopfner KP, Kakadia PM, Schneider S, Dufour A, Braess J, Sauerland MC, Berdel WE, Buchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK and Greif PA (2013). Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia. Blood, 122, 1761-9.

Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T, Yaghmaie M, Dörge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K and Bohlander SK (2012). GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood, 120, 395-403.

Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, Braess J, Sauerland MC, Berdel WE, Buchner T, Woermann BJ, Hiddemann W, Spiekermann K and Bohlander SK (2012). RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica, 97, 1909-15.

Deshpande AJ, Rouhi A, Lin Y, Stadler C, Greif PA, Arseni N, Opatz S, Quintanilla-Fend L, Holzmann K,W, Dohner K, Dohner H, Xu G, Armstrong SA, Bohlander SK and Buske C (2011). The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia, 25, 1718-27.

Greif PA, Eck SH, Konstandin NP, Benet-Pages A, Ksienzyk B, Dufour A, Vetter AT, Popp HD, Lorenz-Depiereux B, Meitinger T, Bohlander SK and Strom TM (2011). Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia, 25, 821-7.

Greif PA, Yaghmaie M, Konstandin NP, Ksienzyk B, Alimoghaddam K, Ghavamzadeh A, Hauser A, Graf A, Krebs S, Blum H and Bohlander SK (2011). Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing. Leukemia, 25, 1519-22.

Greif PA, Tizazu B, Krause A, Kremmer E and Bohlander SK (2008). The leukemogenic CALM/AF10 fusion protein alters the subcellular localization of the lymphoid regulator Ikaros. Oncogene, 27, 2886-96.